{"id":"irx-101","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Thrombosis"}]},"_chembl":{"chemblId":"CHEMBL4594479","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IRX-101 is a polyclonal immunoglobulin G (IgG) preparation derived from pooled human plasma that works through multiple immunomodulatory mechanisms, including Fc receptor engagement, complement modulation, and anti-inflammatory cytokine induction. It is being developed to treat conditions characterized by dysregulated immune responses and excessive inflammation.","oneSentence":"IRX-101 is an intravenous immunoglobulin (IVIG) formulation designed to modulate immune responses and reduce inflammation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:17:14.332Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic inflammatory demyelinating polyneuropathy (CIDP)"}]},"trialDetails":[{"nctId":"NCT05750589","phase":"PHASE3","title":"Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections","status":"NOT_YET_RECRUITING","sponsor":"iRenix Medical, Inc.","startDate":"2025-12-31","conditions":"Retinal Disease","enrollment":240},{"nctId":"NCT05747430","phase":"PHASE2","title":"SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF)","status":"UNKNOWN","sponsor":"iRenix Medical, Inc.","startDate":"2023-02-22","conditions":"Retinal Disease","enrollment":75},{"nctId":"NCT05127525","phase":"PHASE3","title":"EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)","status":"TERMINATED","sponsor":"iRenix Medical, Inc.","startDate":"2021-11-15","conditions":"Diabetic Macular Edema, Branch Retinal Vein Occlusion, Glaucoma/Closed Angle Glaucoma","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Test Arm 1"],"phase":"phase_3","status":"active","brandName":"IRX-101","genericName":"IRX-101","companyName":"iRenix Medical, Inc.","companyId":"irenix-medical-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IRX-101 is an intravenous immunoglobulin (IVIG) formulation designed to modulate immune responses and reduce inflammation. Used for Chronic inflammatory demyelinating polyneuropathy (CIDP).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}